Does UnitedHealthcare Cover Wegovy?

What Does UnitedHealthcare's Default Policy Say About Wegovy?

UnitedHealthcare's commercial plans generally place Wegovy on Tier 3 of the formulary and require prior authorization before the pharmacy will dispense it. The FDA approved semaglutide 2.4 mg (Wegovy) on June 4, 2021, specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher in the presence of at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. [1]

That approval was built on trial data that were difficult to ignore. In STEP-1 (N=1,961), semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% over 68 weeks versus 2.4% with placebo (P<0.001). [2] Those results helped push major commercial payers, including UnitedHealthcare, to develop formal coverage policies rather than blanket exclusions.

UnitedHealthcare separates coverage into two distinct tracks. The first track is employer-sponsored commercial plans, where the employer decides whether weight-management drugs are an included benefit. The second is fully-insured individual and small-group plans governed by state mandates. Because employer plan sponsors can opt in or out of obesity drug coverage under ERISA, two people with UnitedHealthcare cards can have completely different Wegovy benefits depending on where they work.

Check your Summary of Benefits and Coverage (SBC) or call the member services number on your insurance card before assuming coverage exists. The SBC will list "anti-obesity medications" or "weight-loss drugs" as a covered or excluded category.

The American Association of Clinical Endocrinology 2023 guidelines state that "pharmacotherapy for obesity should be considered for all patients with a BMI ≥30, or ≥27 with weight-related comorbidity, who have not achieved adequate response to lifestyle intervention alone." [3] UnitedHealthcare's own clinical criteria generally mirror this language, which means your physician's documentation should use the same framing.

Prior Authorization Criteria for Wegovy on UnitedHealthcare

Prior authorization (PA) is required on essentially every UnitedHealthcare plan that covers Wegovy, and the clinical criteria are specific. Submitting incomplete documentation is the single most common reason for a first-pass denial.

Standard PA criteria across most UHC commercial formularies include:

BMI threshold. Your prescriber must document a BMI of 30 or higher, or a BMI of 27 or higher plus at least one qualifying comorbidity. The FDA label lists hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease as qualifying conditions. [1]

Lifestyle intervention documentation. UHC typically requires evidence that the patient has attempted a structured diet and exercise program. This does not always mean a formal program; a physician's chart note documenting dietary counseling and physical activity goals for a defined period (often 3 to 6 months) may satisfy this requirement. The CDC reports that sustained lifestyle intervention achieves roughly 3 to 5% weight loss on average, providing a clear medical rationale for escalating to pharmacotherapy. [4]

Absence of contraindications. Wegovy carries an FDA boxed warning for thyroid C-cell tumors based on rodent data. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated. [1] UHC PA forms ask prescribers to confirm these contraindications have been assessed.

Prescriber specialty. Some UHC plan variants require that the prescribing physician be a primary care provider, endocrinologist, or obesity medicine specialist. If you are seeing a general practitioner, confirm that your plan does not restrict prescribing to specialists.

The PA authorization period is typically 12 months, after which the prescriber must reauthorize by documenting clinical response. UHC's standard renewal criterion is a body-weight reduction of at least 5% from baseline at the time of initial authorization. A 2022 analysis published in JAMA Network Open found that patients who achieved 5% or greater weight loss at 16 weeks on semaglutide were significantly more likely to reach 10% or greater loss at one year. [5] That data point supports early monitoring and prompt documentation of response.

HealthRX Prior Authorization Submission Checklist for Wegovy / UHC

Before your prescriber submits the PA request, confirm the chart contains:

1. Current measured BMI with date of measurement
2. List of qualifying comorbidities with ICD-10 codes (E11.9 for type 2 diabetes, I10 for hypertension, E78.5 for hyperlipidemia)
3. Documentation of structured lifestyle intervention with duration and type
4. Confirmation of contraindication screening (MTC/MEN2 history, pancreatitis history)
5. Most recent HbA1c if diabetes is the qualifying comorbidity
6. Prescriber NPI and specialty code

Plans that receive all six elements on the initial submission have a materially lower denial rate than those submitted with BMI alone.

What Formulary Tier Is Wegovy On, and What Does That Mean for Cost?

Tier 3 placement means Wegovy sits in the specialty or preferred brand category on most UHC formularies, which typically carries the highest cost-sharing tier below true specialty biologics. Out-of-pocket costs under Tier 3 vary widely by plan design, ranging from a fixed copay of $60, $150 per fill to a 25 to 30% coinsurance after a deductible.

Without insurance coverage, the current list price for Wegovy is approximately $1,349 per month. [6] That figure is consistent across major pharmacy benefit managers because Novo Nordisk has not issued broad wholesale price reductions.

Novo Nordisk operates a savings card program called the Wegovy Savings Offer for commercially insured patients. Eligible patients may pay as little as $0 for a 28-day supply, up to a maximum annual savings cap that Novo Nordisk updates periodically. The savings card cannot be used by patients enrolled in Medicare Part D, Medicaid, or any other federal healthcare program. [6]

For patients whose plans do not cover Wegovy at all, the savings card does not apply to cash-pay scenarios without insurance. In that case, NovoCare patient assistance programs may provide access based on income. The annual household income threshold for NovoCare's free drug program is typically 400% of the federal poverty level. [6]

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes that "cost and insurance coverage remain the primary barriers to initiating and maintaining GLP-1 receptor agonist therapy." [7] Documenting medical necessity clearly is therefore not just a regulatory exercise; it directly affects whether a patient can afford the drug.

Does UnitedHealthcare Require Step Therapy Before Wegovy?

Step therapy is a real barrier on many UHC plans. Step therapy means the plan requires the patient to try and fail one or more less expensive treatments before it will cover the requested drug.

For Wegovy specifically, UHC step therapy protocols vary by plan but most commonly require one of the following prior treatments:

Orlistat (Xenical / Alli). Orlistat 120 mg three times daily is FDA-approved for obesity and is generically available for under $30 per month. A Cochrane systematic review of 11 trials found that orlistat produced approximately 2.9 kg more weight loss than placebo at 12 months, with significant gastrointestinal side effects limiting adherence. [8] Because tolerance is often poor, documenting a trial and discontinuation due to adverse effects satisfies step therapy on most UHC plans.

Phentermine/topiramate extended-release (Qsymia). Some UHC plans list this as an acceptable first-line branded agent that must be tried before semaglutide 2.4 mg.

Naltrexone/bupropion (Contrave). Similarly listed on select formularies as a required step.

Structured intensive behavioral therapy. Some plans accept documentation of participation in a medically supervised low-calorie program (such as an 800, 1,200 kcal/day program for 12 or more weeks) as satisfying the step therapy requirement without requiring a pharmacologic trial.

A critical practical point: step therapy does not always require proof of clinical failure, only proof of a trial. Your prescriber can document that orlistat was prescribed, dispensed, and discontinued, with the reason. A pharmacy fill history printout attached to the PA submission satisfies this requirement on most UHC step therapy forms.

Seventeen states have passed step therapy reform legislation requiring that health plans grant exceptions to step therapy when a prescriber certifies that the required drug is contraindicated, has been tried and failed, or is not clinically appropriate. [9] If your state has such a law, your prescriber can invoke the exception clause directly on the PA form rather than requiring an actual trial.

How to Appeal a UnitedHealthcare Denial of Wegovy

A denial is not the end of the road. UHC's appeals process has two internal levels followed by an external independent review organization (IRO) review, and denial reversal rates at the IRO level for medically necessary specialty drugs are meaningful.

Level 1 Internal Appeal. You or your prescriber must file within 180 days of receiving the Explanation of Benefits (EOB) with the denial. Submit the appeal in writing with supporting clinical documentation. The most effective additions at this stage are:

• A letter of medical necessity from the prescriber that explicitly cites STEP-1 outcomes [2] and the AACE 2023 guidelines [3]
• Current lab work showing metabolic risk (HbA1c, fasting glucose, lipid panel)
• A body weight trajectory chart showing inadequate response to prior interventions
• A statement addressing each specific denial reason listed on the EOB

UHC is required to respond to a Level 1 appeal within 30 calendar days for non-urgent pre-service decisions and within 60 days for post-service claims.

Level 2 Internal Appeal. If Level 1 is denied, you escalate to Level 2. Submit within 60 days of the Level 1 denial letter. At this stage, request a peer-to-peer review between your physician and UHC's medical director. Studies examining peer-to-peer calls for specialty drug denials suggest that approximately 30 to 40% of denials are overturned at this stage when the treating physician participates directly. [10]

External Independent Review. If both internal levels are denied, federal law under the Affordable Care Act requires that UHC provide access to an independent review organization for all non-grandfathered health plans. The IRO reviewer is a clinician who has no financial relationship with UHC. The IRO's decision is binding on the plan. Request external review within 4 months of the final internal denial.

State Insurance Commissioner Complaint. Filing a complaint with your state's insurance department can run concurrently with the IRO process. Some state commissioners fast-track GLP-1 appeals given the volume of complaints received since 2022. [11]

A 2023 brief from the Kaiser Family Foundation found that patients who escalated to external review won their appeals at rates exceeding 40% across multiple drug classes, reinforcing that full escalation is worth pursuing. [12]

How Employer Plan Design Affects Your UHC Wegovy Coverage

The largest variable in Wegovy coverage under UHC is not UHC itself. Self-funded employer plans under ERISA are not required to cover obesity medications, and UHC administers those benefits on the employer's behalf without setting clinical policy. Your employer is the decision-maker.

Employers are increasingly adding GLP-1 coverage as a workforce health investment. A 2024 analysis in JAMA found that employer coverage of GLP-1 receptor agonists was associated with a 3.4% reduction in all-cause medical costs among obese employees over 24 months. [13] Human resources departments responding to that kind of data are revising benefit designs.

If your plan excludes weight-management drugs entirely, your options within the plan are limited unless your employer agrees to add the benefit. However, two pathways may still apply:

Diabetes diagnosis. If you have type 2 diabetes, semaglutide 0.5 to 1 mg weekly (Ozempic) is FDA-approved for glycemic control and is covered on nearly every commercial formulary as a diabetes drug, usually at Tier 2. Ozempic is not the same as Wegovy (which uses a higher 2.4 mg maintenance dose), but it may be accessible when Wegovy is not. Your prescriber should discuss whether this is medically appropriate for your situation.

Medical necessity override. For patients with severe obesity (BMI of 40 or higher) and documented obesity-related organ damage, some self-funded plans grant medical necessity exceptions outside normal formulary rules. This requires a compelling clinical package and often a direct appeal to the plan sponsor's benefits committee.

The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with preexisting cardiovascular disease and overweight or obesity, independent of diabetes status (P<0.001). [14] That evidence is now a standard component of medical necessity letters for patients with cardiovascular risk, because it reframes Wegovy from a "lifestyle drug" to a cardiovascular risk reduction agent.

Monitoring Requirements and Continued Coverage

UHC prior authorizations for Wegovy typically cover an initial 12-month period. Renewal requires documentation that the patient achieved at least 5% body-weight loss from baseline. This criterion comes directly from the FDA-approved prescribing information, which states that patients who do not achieve 5% weight loss after 16 weeks on the 2.4 mg maintenance dose should consider discontinuation. [1]

Your prescriber should document weight at every visit using the same scale and method to build a clear record. The STEP-5 trial (N=304 to 104 weeks) showed that continued semaglutide 2.4 mg produced sustained weight loss of 15.2% versus 2.6% with placebo at two years. [15] That sustained efficacy data supports renewal authorization by demonstrating that ongoing therapy continues to deliver measurable benefit beyond the initial authorization period.

Blood pressure, fasting glucose, and lipid panel results documented at renewal visits strengthen the case that metabolic risk is actively improving under treatment, which is the clinical argument UHC reviewers respond to most consistently.